These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
510 related articles for article (PubMed ID: 19238088)
1. Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features. Sheehan DV; Nemeroff CB; Thase ME; Entsuah R; Int Clin Psychopharmacol; 2009 Mar; 24(2):61-86. PubMed ID: 19238088 [TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Schatzberg A; Roose S Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045 [TBL] [Abstract][Full Text] [Related]
3. Venlafaxine extended-release: a review of its use in the management of major depression. Wellington K; Perry CM CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036 [TBL] [Abstract][Full Text] [Related]
4. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Lenox-Smith AJ; Jiang Q Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. Silverstone PH; Salinas E J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362 [TBL] [Abstract][Full Text] [Related]
6. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870 [TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. Costa e Silva J J Clin Psychiatry; 1998 Jul; 59(7):352-7. PubMed ID: 9714263 [TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Stahl SM; Entsuah R; Rudolph RL Biol Psychiatry; 2002 Dec; 52(12):1166-74. PubMed ID: 12488062 [TBL] [Abstract][Full Text] [Related]
9. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668 [TBL] [Abstract][Full Text] [Related]
10. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study]. Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291 [TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. Nemeroff CB; Thase ME; J Psychiatr Res; 2007; 41(3-4):351-9. PubMed ID: 16165158 [TBL] [Abstract][Full Text] [Related]
12. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. Khan A; Upton GV; Rudolph RL; Entsuah R; Leventer SM J Clin Psychopharmacol; 1998 Feb; 18(1):19-25. PubMed ID: 9472838 [TBL] [Abstract][Full Text] [Related]
13. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Tzanakaki M; Guazzelli M; Nimatoudis I; Zissis NP; Smeraldi E; Rizzo F Int Clin Psychopharmacol; 2000 Jan; 15(1):29-34. PubMed ID: 10836283 [TBL] [Abstract][Full Text] [Related]
14. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study. Wang G; Gislum M; Filippov G; Montgomery S Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503 [TBL] [Abstract][Full Text] [Related]
15. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. Entsuah AR; Huang H; Thase ME J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046 [TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. Mehtonen OP; Søgaard J; Roponen P; Behnke K J Clin Psychiatry; 2000 Feb; 61(2):95-100. PubMed ID: 10732656 [TBL] [Abstract][Full Text] [Related]
17. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Mallick R; Chen J; Entsuah AR; Schatzberg AF J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275 [TBL] [Abstract][Full Text] [Related]
18. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. Montgomery SA; Tobias K; Zornberg GL; Kasper S; Pande AC J Clin Psychiatry; 2006 May; 67(5):771-82. PubMed ID: 16841627 [TBL] [Abstract][Full Text] [Related]
20. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]